8-K: Current report filing
Published on October 21, 2002
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported): October 16, 2002
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| Virginia |
001-13467 |
56-1641133 | ||
| (State or Other Jurisdiction of
Incorporation) |
(Commission File
Number) |
(IRS Employer Identification
No.) |
601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)
Registrants telephone number, including area code: (804) 648-3820
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(a) Financial statements of businesses acquired.
N/A
(b) Pro forma financial information.
N/A
(c) Exhibits.
| 99.1 |
Press release, dated October 16, 2002, relating to the registrants financial performance for the fiscal quarter
ended September 30, 2002. |
.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| COMMONWEALTH BIOTECHNOLOGIES, INC. | ||
| By: |
/s/ ROBERT B. HARRIS, PH.D. | |
| Robert B. Harris, Ph.D. President and Chief Executive Officer | ||
Dated: October 18, 2002
3
EXHIBIT INDEX
| Number |
Description of Exhibit | |
| 99.1 |
Press release, dated October 16, 2002, relating to the registrants financial performance for the fiscal quarter
ended September 30, 2002. |
4